We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam's LDL-Lowering Drug Positive in Phase II Study
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) and its partner The Medicines Company announced positive final results from the phase II study, ORION-1, on their experimental PCSK9 inhibitor, inclisiran, which is being developed for the treatment of hypercholesterolemia.
Alnylam’s share price has increased 47.6% year to date, while the Zacks classified Medical Biomedical and Genetics industry gained 8%.
ORION-1 is a placebo-controlled, double-blinded, randomized, dose-finding phase II study. It compares and evaluates the effect of various doses of single or multiple subcutaneous injections of inclisiran. The study compares the effect of different doses of inclisiran and evaluates the potential for an infrequent dosing regimen.
The data from ORION-1 showed that inclisiran resulted in significant reductions of LDL-C (low-density lipoprotein ). Also, the study showed high standards of safety and tolerability.
The trial randomized 497 patients and the mean baseline LDL-C was about 130 mg/dL. The optimal starting dose regimen (300 mg injection administered on day-1 and day-90) achieved a mean LDL-C reduction of 52.6% and up to 81% at Day-180, and a time-adjusted mean of greater than 50% for the six month period from Day-90 through Day-270.
For all the dose groups the differences in the primary (LDL-C) and secondary (PCSK9) endpoints between inclisiran and placebo were statistically significant (p <0.0001). The results were presented at the American College of Cardiology’s 66th Annual Scientific Session, ACC.17, and have been published on Mar 17, 2017 online issue of The New England Journal of Medicine.
Moving ahead, the company expects to move Inclisiran into phase III development including the initiation of ORION-4.
In Jan 2017, The Medicines Company announced positive top-line results from a day 180 interim analysis of the ongoing ORION-1 phase II study on Inclisiran. The study was conducted in a total of 501 patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (hypercholesterolemia).
Moreover, the interim data demonstrated that inclisiran led to a significant and durable reduction of LDL (low-density lipoprotein) cholesterol up to Day 210. Inclisiran was well tolerated throughout the study, with infrequent and mild or moderate injection site reactions. Additionally, the company announced the initiation of ORION-2 for evaluating the efficacy, safety and tolerability of Inclisiran in patients with homozygous familial hypercholesterolemia (HoFH).
Alnylam is a Zacks Rank #3 (Hold) stock. Some other better-ranked stocks in the health care sector include Heska Corp. and Retrophin, Inc. . Heska and Retrophin carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.53 to $1.65 for 2017 and from $1.90 to $2.01 for 2018, over the last 30 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 291.54%. Its share price increased 30% year to date.
Retrophin’s loss estimates narrowed from 85 cents to 72 cents for 2017 and from 67 cents to 53 cents for 2018, over the last 30 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 80.55%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time. One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alnylam's LDL-Lowering Drug Positive in Phase II Study
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) and its partner The Medicines Company announced positive final results from the phase II study, ORION-1, on their experimental PCSK9 inhibitor, inclisiran, which is being developed for the treatment of hypercholesterolemia.
Alnylam’s share price has increased 47.6% year to date, while the Zacks classified Medical Biomedical and Genetics industry gained 8%.
ORION-1 is a placebo-controlled, double-blinded, randomized, dose-finding phase II study. It compares and evaluates the effect of various doses of single or multiple subcutaneous injections of inclisiran. The study compares the effect of different doses of inclisiran and evaluates the potential for an infrequent dosing regimen.
The data from ORION-1 showed that inclisiran resulted in significant reductions of LDL-C (low-density lipoprotein ). Also, the study showed high standards of safety and tolerability.
The trial randomized 497 patients and the mean baseline LDL-C was about 130 mg/dL. The optimal starting dose regimen (300 mg injection administered on day-1 and day-90) achieved a mean LDL-C reduction of 52.6% and up to 81% at Day-180, and a time-adjusted mean of greater than 50% for the six month period from Day-90 through Day-270.
For all the dose groups the differences in the primary (LDL-C) and secondary (PCSK9) endpoints between inclisiran and placebo were statistically significant (p <0.0001). The results were presented at the American College of Cardiology’s 66th Annual Scientific Session, ACC.17, and have been published on Mar 17, 2017 online issue of The New England Journal of Medicine.
Moving ahead, the company expects to move Inclisiran into phase III development including the initiation of ORION-4.
In Jan 2017, The Medicines Company announced positive top-line results from a day 180 interim analysis of the ongoing ORION-1 phase II study on Inclisiran. The study was conducted in a total of 501 patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (hypercholesterolemia).
Moreover, the interim data demonstrated that inclisiran led to a significant and durable reduction of LDL (low-density lipoprotein) cholesterol up to Day 210. Inclisiran was well tolerated throughout the study, with infrequent and mild or moderate injection site reactions. Additionally, the company announced the initiation of ORION-2 for evaluating the efficacy, safety and tolerability of Inclisiran in patients with homozygous familial hypercholesterolemia (HoFH).
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. Price | Alnylam Pharmaceuticals, Inc. Quote
Zacks Rank & Other Key Picks
Alnylam is a Zacks Rank #3 (Hold) stock. Some other better-ranked stocks in the health care sector include Heska Corp. and Retrophin, Inc. . Heska and Retrophin carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.53 to $1.65 for 2017 and from $1.90 to $2.01 for 2018, over the last 30 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 291.54%. Its share price increased 30% year to date.
Retrophin’s loss estimates narrowed from 85 cents to 72 cents for 2017 and from 67 cents to 53 cents for 2018, over the last 30 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 80.55%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time. One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>